295 related articles for article (PubMed ID: 19616371)
1. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
2. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.
Cho SJ; Kim YJ; Surh YJ; Kim BM; Lee SK
J Biol Chem; 2011 Jun; 286(22):19662-71. PubMed ID: 21478145
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Zhong L; Yang S; Jia Y; Lei K
J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
[TBL] [Abstract][Full Text] [Related]
4. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.
Liao YJ; Bai HY; Li ZH; Zou J; Chen JW; Zheng F; Zhang JX; Mai SJ; Zeng MS; Sun HD; Pu JX; Xie D
Cell Death Dis; 2014 Mar; 5(3):e1137. PubMed ID: 24651440
[TBL] [Abstract][Full Text] [Related]
5. NCPMF-60 induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells.
Dai QS; Liu W; Wang XB; Lu N; Gong DD; Kong LY; Guo QL
Anticancer Drugs; 2011 Jan; 22(1):46-57. PubMed ID: 20948430
[TBL] [Abstract][Full Text] [Related]
6. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
[TBL] [Abstract][Full Text] [Related]
8. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
9. Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance.
Haider C; Grubinger M; Řezníčková E; Weiss TS; Rotheneder H; Miklos W; Berger W; Jorda R; Zatloukal M; Gucky T; Strnad M; Kryštof V; Mikulits W
Mol Cancer Ther; 2013 Oct; 12(10):1947-57. PubMed ID: 23939380
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of di-n-butyl-(2,6-difluorobenzohydroxamato)tin(IV) against human gastric carcinoma SGC-7901 cells via G2/M cell cycle arrest and cell apoptosis.
Yunlan L; Juan Z; Qingshan L
PLoS One; 2014; 9(3):e90793. PubMed ID: 24643073
[TBL] [Abstract][Full Text] [Related]
11. Identification of a 3,3-difluorinated tetrahydropyridinol compound as a novel antitumor agent for hepatocellular carcinoma acting via cell cycle arrest through disturbing CDK7-mediated phosphorylation of Cdc2.
Bi W; Xiao JC; Liu RJ; Zhou LY; Zhang S; Yang M; Zhang PF
Invest New Drugs; 2020 Apr; 38(2):287-298. PubMed ID: 31076964
[TBL] [Abstract][Full Text] [Related]
12. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
13. Nitidine chloride induces apoptosis in human hepatocellular carcinoma cells through a pathway involving p53, p21, Bax and Bcl-2.
Ou X; Lu Y; Liao L; Li D; Liu L; Liu H; Xu H
Oncol Rep; 2015 Mar; 33(3):1264-74. PubMed ID: 25530218
[TBL] [Abstract][Full Text] [Related]
14. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Byth KF; Thomas A; Hughes G; Forder C; McGregor A; Geh C; Oakes S; Green C; Walker M; Newcombe N; Green S; Growcott J; Barker A; Wilkinson RW
Mol Cancer Ther; 2009 Jul; 8(7):1856-66. PubMed ID: 19509270
[TBL] [Abstract][Full Text] [Related]
15. Hemistepsin A Inhibits Cell Proliferation and Induces G0/G1-Phase Arrest, Cellular Senescence and Apoptosis Via the AMPK and p53/p21 Signals in Human Hepatocellular Carcinoma.
Baek SY; Hwang UW; Suk HY; Kim YW
Biomolecules; 2020 May; 10(5):. PubMed ID: 32375410
[TBL] [Abstract][Full Text] [Related]
16. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
Shi XN; Li H; Yao H; Liu X; Li L; Leung KS; Kung HF; Lu D; Wong MH; Lin MC
PLoS One; 2015; 10(7):e0132072. PubMed ID: 26147897
[TBL] [Abstract][Full Text] [Related]
17. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
[TBL] [Abstract][Full Text] [Related]
18. Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma.
Li KK; Ng IO; Fan ST; Albrecht JH; Yamashita K; Poon RY
Liver; 2002 Jun; 22(3):259-68. PubMed ID: 12100577
[TBL] [Abstract][Full Text] [Related]
19. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
[TBL] [Abstract][Full Text] [Related]
20. (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.
Pei T; Meng Q; Han J; Sun H; Li L; Song R; Sun B; Pan S; Liang D; Liu L
Oncotarget; 2016 Jul; 7(28):43475-43491. PubMed ID: 27259268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
